For nearly two years, U-M neurologist Eva Feldman, M.D., Ph.D. has led the nation’s first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig’s disease. Now, a new approval from the FDA paves the way for U-M to become the second site in the trial,
An update on the status of bringing an innovative clinical trial for ALS to Michigan.
The first published results from an early-stage clinical trial show that spinal cord stem cells can be delivered safely into the spines of patients with the condition commonly known as Lou Gehrig's disease, opening the door for further research on this innovative approach.
Physician-scientists worldwide will vie for the newly-established $100,000 annual Taubman Prize for Excellence in Translational Medical Science starting in 2012, the A. Alfred Taubman Medical Research Institute has announced.
Eva Feldman, M.D., Ph.D., will become president of the American Neurological Association.
The second round of Taubman Scholars has been announced at the University of Michigan's A. Alfred Taubman Medical Research Institute.
